Skip to main content

Rheumatoid Arthritis

      The last day was jammed with important reports and research including the late breaking abstracts.    What imaging modality is best in GCA? Dutch study: n=42 ?GCA got all three of USS,…
      Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR Convergence 2022 suggests that even in…
      RT @RichardPAConway: Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commeric
      Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
      RT @drdavidliew: Which is better for CV risk in RA:
      triple therapy DMARDs or TNFi?

      TARGET study
      n=159 using PET/CT sur
      2 years ago
      Which is better for CV risk in RA: triple therapy DMARDs or TNFi? TARGET study n=159 using PET/CT surrogate (endpoint responsiveness👀) - either led to benefit - both equally good - benefit *not* linked to change in DAS28 A direct CV effect of RA Rx? ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
      RT @RichardPAConway: Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR
      Singh @NamrataRheum et al. Frailty in patients treated bDMARD/tsDMARD assoc serious infections aHR 1.34, any infection aHR 1.18, hospitalisation aHR 1.34 (all relative non-frail). @RheumNow #ACR22 Abstr#2218 https://t.co/ONsTBq8ehB https://t.co/iTVANh5flk
      RT @AurelieRheumo: 💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks

      Insom
      💤cognitive behavioural therapy 2 hours/wk for 6 wks for insomnia improves RA PROs at 26 wks Insomnia Severity Index -9.8 RAID -1.4 PGA -13 Small sample size wk6 trend improvement sleep efficiency 89% vs84% p=0.07 but not wk26 https://t.co/rpKdtbREYs Abs#2188 #ACR22 @RheumNow https://t.co/kEBcPAdIKW
      RT @synovialjoints: Peresolimab humanized IgG1 mab
      ➢ stimulates PD-1 & physiological immune inhibitory pathways
      âž
      Peresolimab humanized IgG1 mab ➢ stimulates PD-1 & physiological immune inhibitory pathways ➢ In RA phase 2 study, superior to placebo at Week 12 DAS28/CDAI ➢ safety events were similar between treatment groups Emery P #L03 https://t.co/4Jd79CW5RA #ACR22 #ACRBest @RheumNow https://t.co/PSuLQgjYuz
      Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, J
      2 years ago
      Tonight at 7pm ET! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22 https://t.co/hIH4WghLwN https://t.co/oKQbBnMiqQ